Home / Email Lists / Lead Database / martin yateman

Generic illustrated contact avatar
Illustrative avatar—not the contact's photograph.
Protected Email Contact

martin yateman — Director, Preclinical & Clinical Bioanalysis at Kymab Ltd in United Kingdom

Review available professional, company and location information for this protected LastDatabase contact record. Contact details remain protected until authorized purchase.

Director, Preclinical & Clinical Bioanalysis at Kymab Ltd Kymab Ltd biotechnology Cambridge, England, United Kingdom

Professional & Business Information

Available public profile attributes for this protected contact record.

Contact Name martin yateman
Record Type Email
Job Title Director, Preclinical & Clinical Bioanalysis at Kymab Ltd
Company Kymab Ltd
Industry biotechnology
Country United Kingdom
State / Region England
City Cambridge
Technology 123-reg_dns,mimecast,digitalocean,ubuntu,django,google_analytics,typekit,nginx,mobile_friendly

About the Person

Full Name
Martin Yateman
Job Title
Director, Preclinical & Clinical Bioanalysis at Kymab Ltd
Seniority
director
Detailed Function
preclinical clinical bioanalysis at kymab ltd
City
Cambridge
State / Region
England
Country
United Kingdom
Professional Profile
LinkedIn Profile ↗

About the Company

Company Name
Kymab Ltd
Domain
kymab.com
Industry
biotechnology
Employee Size
114
Founded Year
2010
Headquarters Country
United Kingdom
Headquarters Postal Code
CB22 3AT
Company Languages
English
Specialties
fully human monoclonal antibodies, drug discovery, drug development, advanced human antibody drug discovery & development, biotechnology
Technologies
123-reg_dns,mimecast,digitalocean,ubuntu,django,google_analytics,typekit,nginx,mobile_friendly

Company Description

Kymab, based in Cambridge, UK, is working independently and with partners to provide novel solutions in drug and vaccine development. Using our unique technology, we rapidly develop broad diversity, high-quality human antibodies for treating challenging diseases. We are building a rich pipeline of assets in four main therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases, with clinical studies expected to begin in 2017.

About This Contact Record

This LastDatabase profile represents an available email contact record for martin yateman.

The listed professional role is Director, Preclinical & Clinical Bioanalysis at Kymab Ltd. The associated company is Kymab Ltd.

The record is associated with Cambridge, England, United Kingdom. Buyers should confirm that the location and professional context fit their intended use before purchasing.

The available industry classification is biotechnology. Classification reflects the information currently associated with this database record.

More Contacts in This Database

Browse other protected records from the same database. Contact values remain protected.

Data Quality & Responsible Access

LastDatabase protects contact values before purchase and provides contextual information so customers can evaluate relevance before access.

Protected Contact Data Full contact values are not displayed publicly on this profile.
Server-Validated Purchase Eligible purchases are validated against the package, lead type, record ID and current server-side price.
Responsible Use Buyers remain responsible for applicable privacy, marketing and opt-out rules.

Consent Evidence, Privacy & Responsible Use

LastDatabase retains private source-provenance and consent documentation where available in the original source data. Supporting evidence may include collection timestamps, source references, opt-in information and other audit information.

Private evidence is not displayed publicly because it may contain personal or confidential information. It may be retained for legitimate compliance, correction, suppression and audit purposes.

Purchasing access to a contact does not create unrestricted permission to contact an individual. Buyers must ensure that their intended email, SMS, telephone or other outreach complies with applicable privacy, direct-marketing and opt-out requirements.

Buyers should accurately identify themselves, provide required opt-out mechanisms and promptly honor valid do-not-contact or suppression requests.

Reference guidance: FTC CAN-SPAM compliance guidance and ICO privacy information guidance .

Live Chat